TTNP - タイタン・ファ―マシュ―ティカルズ (Titan Pharmaceuticals Inc.)

TTNPのニュース

   Titan's Probuphine® Commercialization Partner, Molteni, Enters Into Exclusive European Distribution Agreement With Accord Healthcare  2020/09/15 12:30:00 PR Newswire
SOUTH SAN FRANCISCO, Calif., Sept. 15, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that its partner, Molteni Farmaceutici ("Molteni"), has entered into an exclusive distribution agreement with Accord Healthcare Europe…
   Titan Pharmaceuticals Provides Update To Stockholders On Proposal To Amend Its Certificate Of Incorporation  2020/09/14 12:30:00 PR Newswire
SOUTH SAN FRANCISCO, Calif., Sept. 14, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today provided an update on the upcoming special meeting of stockholders (the "Meeting") in response to recent stockholder inquiries regarding the number of…
   Titan Pharmaceuticals Reports Second Quarter 2020 Financial Results  2020/08/14 08:45:00 Benzinga
SOUTH SAN FRANCISCO, Calif., Aug. 14, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) ("Titan" or the "Company") today …
   Thinking about buying stock in SINTX Technologies, Kitov Pharma, Titan Pharmaceuticals, T-Mobile, or Nio Inc?  2020/06/24 14:30:00 PR Newswire
NEW YORK, June 24, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SINT, KTOV, TTNP, TMUS, and NIO. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
   Titan Pharmaceuticals And Indegene Enter Into Probuphine® Co-Promotion Partnership  2020/06/24 12:00:00 PR Newswire
SAN FRANCISCO, June 24, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has entered into a co-promotion partnership with Indegene Inc. to establish multichannel digital marketing programs throughout the United States and…
   Titan Pharmaceuticals Launches Virtual REMS Training For Probuphine Health Care Providers  2020/06/16 12:00:00 PR Newswire
/PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has initiated a fully-virtual Probuphine®…
   Titan Pharmaceuticals, Inc. (TTNP): Q4 2019 Earnings Snapshot  2020/03/30 20:12:07 news.alphastreet.com
— Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) reported a loss of $0.08 per share in the fourth quarter of 2019, in line with Wall Street expectation. — Q4 revenue was flat at $1.2 million, vs. $920,000 expected. — As at December 31, 2019, Titan had cash and cash equivalents of approximately $5.2 million. — Launch of […]
   Titan Pharmaceuticals Announces Pricing of $2.2 Million Registered Direct Offering  2020/01/07 14:15:00 Benzinga Feeds
SOUTH SAN FRANCISCO, Calif. , Jan. 7, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP ) today announced it has entered into a securities purchase agreement with certain accredited institutional investors to purchase approximately $2.2 million of its common stock in a registered direct offering and warrants to purchase shares of common stock in a concurrent private placement. The combined purchase price for one share of common stock and each warrant will be $0.25 . Under the terms of the purchase agreement, Titan has agreed to sell 8,700,000 shares of its common stock. In a concurrent private placement, Titan has agreed to issue warrants to purchase up to an aggregate of 8,700,000 shares of common stock. The warrants will be exercisable commencing on the later of (i) six months from the date of issuance or (ii) the date that Titan's stockholders approve a reverse stock split in an amount sufficient to permit the exercise in full of all of the warrants, will expire on the five year and six month anniversary of the issuance date and will have an exercise price of $0.25 per share.
   Titan Pharmaceuticals Appoints Dr. Kate DeVarney To Its Board Of Directors  2019/12/30 13:01:09 MarketScreener
SOUTH SAN FRANCISCO, Calif., Dec. 30, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. today announced that at its recent annual stockholders meeting, Kate DeVarney, Ph.D., its Executive Vice…
   Titan Pharmaceuticals Reports Third Quarter 2019 Financial Results  2019/11/14 21:03:00 PR Newswire
SOUTH SAN FRANCISCO, Calif., Nov. 14, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today reported financial results for the third quarter ended September 30, 2019 and provided an update on its business. Third Quarter 2019 and Recent Business Highlights In July 2019,…
   Titan Pharmaceuticals, Inc. (TTNP): Q4 2019 Earnings Snapshot  2020/03/30 20:12:07 news.alphastreet.com
— Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) reported a loss of $0.08 per share in the fourth quarter of 2019, in line with Wall Street expectation. — Q4 revenue was flat at $1.2 million, vs. $920,000 expected. — As at December 31, 2019, Titan had cash and cash equivalents of approximately $5.2 million. — Launch of […]
   Titan Pharmaceuticals Announces Pricing of $2.2 Million Registered Direct Offering  2020/01/07 14:15:00 Benzinga Feeds
SOUTH SAN FRANCISCO, Calif. , Jan. 7, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP ) today announced it has entered into a securities purchase agreement with certain accredited institutional investors to purchase approximately $2.2 million of its common stock in a registered direct offering and warrants to purchase shares of common stock in a concurrent private placement. The combined purchase price for one share of common stock and each warrant will be $0.25 . Under the terms of the purchase agreement, Titan has agreed to sell 8,700,000 shares of its common stock. In a concurrent private placement, Titan has agreed to issue warrants to purchase up to an aggregate of 8,700,000 shares of common stock. The warrants will be exercisable commencing on the later of (i) six months from the date of issuance or (ii) the date that Titan's stockholders approve a reverse stock split in an amount sufficient to permit the exercise in full of all of the warrants, will expire on the five year and six month anniversary of the issuance date and will have an exercise price of $0.25 per share.
   Titan Pharmaceuticals Appoints Dr. Kate DeVarney To Its Board Of Directors  2019/12/30 13:01:09 MarketScreener
SOUTH SAN FRANCISCO, Calif., Dec. 30, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. today announced that at its recent annual stockholders meeting, Kate DeVarney, Ph.D., its Executive Vice…
   Titan Pharmaceuticals Reports Third Quarter 2019 Financial Results  2019/11/14 21:03:00 PR Newswire
SOUTH SAN FRANCISCO, Calif., Nov. 14, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today reported financial results for the third quarter ended September 30, 2019 and provided an update on its business. Third Quarter 2019 and Recent Business Highlights In July 2019,…
   The Daily Biotech Pulse: Intuitive Surgical Earnings, Paratek Pulls Out European Application For Antibiotic, Amgen's Evenity In Europe  2019/10/18 11:07:56 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 17) Applied Therapeutics Inc (NASDAQ: APLT ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Celgene Corporation (NASDAQ: CELG ) Kodiak Sciences Inc (NASDAQ: KOD ) The Medicines Company (NASDAQ: MDCO ) Reata Pharmaceuticals Inc (NASDAQ: RETA ) Down In The Dumps (Biotech stocks hitting 52-week lows on Oct. 17) Aileron Therapeutics Inc (NASDAQ: ALRN ) Alpine Immune Sciences Inc (NASDAQ: ALPN ) Diffusion Pharmaceuticals Inc (NASDAQ: DFFN ) Fulcrum Therapeutics Inc (NASDAQ: FULC ) Homology Medicines Inc (NASDAQ: FIXX ) ITAMAR MED LTD/S ADR (NASDAQ: ITMR ) Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA ) Mirum Pharmaceuticals Inc (NASDAQ: MIRM ) Neurometrix Inc (NASDAQ: NURO ) (reacted to its third-quarter results) Puma Biotechnology Inc (NASDAQ: PBYI ) Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL ) Spring Bank Pharmaceuticals Inc (NASDAQ: SBPH ) Theratechnologies Inc (NASDAQ: THTX ) Titan Pharmaceuticals, Inc. (NASDAQ: TTNP ) Stocks In Focus Intuitive Surgical Q3 Tops Expectations Intuitive Surgical, Inc. (NASDAQ: ISRG ) reported third-quarter earnings per share of $3.43 on revenues of $1.13 billion.

calendar